There is an urgent need for improved diagnostic tools and targeted therapies to address the gap in care for patients with ...

Researchers gathered real-world data on biologic therapy to determine the feasibility of targeting clinical remission when ...

A recent novel study published in the New England Journal of Medicine found that Depemokimab can reduce asthma exacerbations ...

Warning signs of asthma include frequent coughing, wheezing, shortness of breath, chest tightness, and increased fatigue.

The first-in class medicine for severe asthma co-developed by AstraZeneca and Amgen is poised for accelerated approval after the US Food and Drug Administration granted it a breakthrough designation.

AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation suitable for administration by patients themselves. The green light for ...

Study objectives: To document the existence and investigate the etiology of "thunderstorm asthma," which has been reported sporadically over the past 20 years. Design: We assessed the relationship ...

The changing atmosphere and dryness in the air can aggravate asthma symptoms Read this article to know how to treat it ...

Further work is required to understand the mechanism underlying the observed effects and to establish whether elements of this intervention may be clinically valuable in patients with severe asthma.

Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further ...

Severe thunderstorms can be quite localised and can develop ... Never shelter under small groups of (or single) trees. The Bureau doesn't issue thunderstorm asthma warnings. Check with your state or ...

HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement ...